{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:12:52Z","timestamp":1762866772716},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jhep.2015.12.004","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T00:44:05Z","timestamp":1450226645000},"page":"807-812","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients"],"prefix":"10.1016","volume":"64","author":[{"given":"Sebastiaan J.","family":"Hullegie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.A.","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido E.L.","family":"van den Berk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan T.M.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Posthouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny N.","family":"Lauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliane M.S.","family":"Leyten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Koopmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"van Eeden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter F.W.","family":"Bierman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid M.","family":"Newsum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joop E.","family":"Arends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart J.A.","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.12.004_b0005","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1097\/QAI.0000000000000208","article-title":"Stabilizing incidence of hepatitis C virus infection among men who have sex with men in Amsterdam","volume":"66","author":"Vanhommerig","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jhep.2015.12.004_b0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.12.004_b0015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cmi.2015.03.026","article-title":"Current knowledge and future perspectives on acute hepatitis C infection","volume":"21","author":"Hullegie","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.jhep.2015.12.004_b0020","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/hep.26991","article-title":"Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin","volume":"59","author":"Santantonio","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.12.004_b0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3851\/IMP1501","article-title":"Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort","volume":"15","author":"Vogel","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2015.12.004_b0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study","volume":"43","author":"Wiegand","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.12.004_b0035","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","article-title":"Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response","volume":"130","author":"Kamal","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.12.004_b0040","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.12.004_b0045","first-page":"43","article-title":"Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management","volume":"69","author":"Arends","year":"2011","journal-title":"Neth J Med"},{"key":"10.1016\/j.jhep.2015.12.004_b0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference","volume":"25","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2015.12.004_b0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.12.004_b0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial","volume":"13","author":"Sulkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.12.004_b0065","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/cid\/cit799","article-title":"Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men","volume":"58","author":"Fierer","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.12.004_b0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAD.0b013e32831940a3","article-title":"Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV","volume":"23","author":"Thomson","year":"2009","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2015.12.004_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QCO.0b013e3283422e09","article-title":"Acute hepatitis C infection in HIV-positive patients","volume":"24","author":"Vogel","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jhep.2015.12.004_b0080","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jhealeco.2005.07.008","article-title":"Using rank data to estimate health state utility models","volume":"25","author":"McCabe","year":"2006","journal-title":"J Health Econ"},{"key":"10.1016\/j.jhep.2015.12.004_b0085","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0b013e3283480144","article-title":"Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration","volume":"25","author":"Lambers","year":"2011","journal-title":"Aids"},{"key":"10.1016\/j.jhep.2015.12.004_b0090","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1097\/00002030-200310170-00011","article-title":"Mortality and progression to AIDS after starting highly active antiretroviral therapy","volume":"17","author":"van Sighem","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2015.12.004_b0095","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2015.12.004_b0100","unstructured":"Lundgren J, Gatell J, Rockstroh J, Furrer H. EACS Guidelines Version 8.0. 2015."},{"key":"10.1016\/j.jhep.2015.12.004_b0105","series-title":"Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1 infected individuals (SWIFT-C)","author":"Naggie","year":"2015"},{"key":"10.1016\/j.jhep.2015.12.004_b0110","series-title":"Sofosbuvir and ribavirin for six weeks is not effective among people with acute and recently acquired HCV infection: the DARE-C 2 Study","author":"Martinello","year":"2015"},{"key":"10.1016\/j.jhep.2015.12.004_b0115","series-title":"Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. SLAM C study","author":"Basu","year":"2015"},{"key":"10.1016\/j.jhep.2015.12.004_b0120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","article-title":"Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2015.12.004_b0125","doi-asserted-by":"crossref","first-page":"ofv026","DOI":"10.1093\/ofid\/ofv026","article-title":"Incident hepatitis C virus infections in the swiss HIV cohort study: changes in treatment uptake and outcomes between 1991 and 2013","volume":"2","author":"Wandeler","year":"2015","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815008053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815008053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T11:21:00Z","timestamp":1653823260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815008053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0168827815008053"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.12.004","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}